Antibody-drug conjugate achieves high response rates as frontline treatment in aggressive, rare blood cancer

Seventy-five percent of patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN) who were treated with the antibody ...

Clinical practice guidelines on frontline and relapsed/refractory management published

The American Society of Hematology (ASH) released guidelines on frontline management of acute lymphoblastic leukemia (ALL) in ...
Benzinga.com

Aptevo Therapeutics Says Two Additional Patients In Early-Stage Leukemia Trial Achieve Remission Within 30 Days of Treatment

90% of frontline AML patients achieved remission with mipletamig plus ven/aza, surpassing the 66% rate seen with ven/aza alone. No cytokine release syndrome (CRS) has been reported in the RAINIER ...
Targeted Oncology

ASH Releases New Guidelines for ALL Care in Adolescents and Young Adults

The American Society of Hematology (ASH) has published new clinical practice guidelines for the management of acute lymphocytic leukemia (ALL) in adolescents and young adults (AYAs). 1 ...
Targeted Oncology

The Paradox of Progress: Personalizing First-Line Therapy in CLL

Expert breaks down CLL frontline choices, IGHV and p53 risk, and what fits patient life. The treatment landscape for chronic lymphocytic leukemia (CLL) has undergone a seismic shift, moving from the ...
Becker's Hospital Review

Study Assesses Impact of Engaged Frontline Staff on Patient Outcomes

Fifteen healthcare organizations, including Loma Linda University Medical Center, have been selected to participate in a national study intended to enhance patient safety and quality of care in health ...
Seeking Alpha

RAINIER Trial Data Update: Two Additional AML Patients Achieve Remission Within 30 Days of Treatment

SEATTLE, WA / ACCESS Newswire / March 20, 2025 / Aptevo Therapeutics (APVO), a clinical-stage biotechnology company developing novel bispecific immuno-oncology therapeutics based on its proprietary ...
Morningstar

Inside Information: Faron to Advance Bexmarilimab into a Registrational Phase 2/3 Study in Treatment-Naïve (frontline) HR-MDS after Positive Meeting with the FDA

TURKU, FI / ACCESS Newswire / August 18, 2025 / Faron Pharmaceuticals Ltd. (AIM:FARN)(First North:FARON), a clinical-stage biopharmaceutical company focused on tackling cancers through novel ...